Savara to Present at the Oppenheimer 33rd Annual Healthcare Conference

Rhea-AI Summary

Savara Inc. (NASDAQ: SVRA) announced its management team's participation at the Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023, at 1:20pm ET. A live webcast of the presentation will be available on Savara's website and archived for 90 days.

The company focuses on rare respiratory diseases and is in Phase 3 development of its lead program, molgramostim nebulizer solution, targeting autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via the investigational eFlow® Nebulizer System, developed in collaboration with PARI Pharma GmbH.

AUSTIN, Texas--(BUSINESS WIRE)-- Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at the Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023 at 1:20pm ET. A live webcast of the presentation will be available on Savara’s website at www.savarapharma.com/investors/events-presentations/ and will be archived for 90 days.

About Savara

Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/).

View source version on businesswire.com: https://www.businesswire.com/news/home/20230306005084/en/

Savara Inc. IR & PR

Anne Erickson

anne.erickson@savarapharma.com

(512) 851-1366

Source: Savara Inc.

FAQ

When will Savara Inc. present at the Oppenheimer 33rd Annual Healthcare Conference?

Savara Inc. will present on March 13, 2023, at 1:20pm ET.

What is the focus of Savara Inc.?

Savara Inc. focuses on rare respiratory diseases.

What is molgramostim and its significance for Savara Inc.?

Molgramostim is Savara's lead program in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).

How can I watch the Savara Inc. presentation from the Oppenheimer conference?

The presentation will be available via live webcast on Savara's website.

What is the delivery system for molgramostim?

Molgramostim is delivered using the investigational eFlow® Nebulizer System.